Abstract:Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a class of severe and chronic diseases of the gastrointestinal (GI) tract with recurrent symptoms and significant morbidity. Long-term persistence of chronic inflammation in IBD is a major contributing factor to neoplastic transformation and the development of colitis-associated colorectal cancer. Conversely, persistence of transmural inflammation in CD is associated with formation of fibrosing strictures, resulting in substantial morbidity. The recent introduction of biological response modifiers as IBD therapies, such as antibodies neutralizing tumor necrosis factor (TNF)-α, have replaced nonselective anti-inflammatory corticosteroids in disease management. However, a large proportion (~40%) of patients with the treatment of anti-TNF-α antibodies are discontinued or withdrawn from therapy because of (1) primary nonresponse, (2) secondary loss of response, (3) opportunistic infection, or (4) onset of cancer. Therefore, the development of novel and effective therapeutics targeting specific signaling pathways in the pathogenesis of IBD is urgently needed. In this comprehensive review, we summarize the recent advances in drug discovery of new small molecules in preclinical or clinical development for treating IBD that target biologically relevant pathways in mucosal inflammation. These include intracellular enzymes (Janus kinases, receptor interacting protein, phosphodiesterase 4, IκB kinase), integrins, G protein-coupled receptors (S1P, CCR9, CXCR4, CB2) and inflammasome mediators (NLRP3), etc. We will also discuss emerging evidence of a distinct mechanism of action, bromodomain-containing protein 4, an epigenetic regulator of pathways involved in the activation, communication, and trafficking of immune cells. We highlight their chemotypes, mode of actions, structure-activity relationships, characterizations, and their in vitro/in vivo activities and therapeutic potential. The perspectives on the relevant challenges, new opportunities, and future directions in this field are also discussed.

Toll-Like Receptors And Inflammatory Bowel Disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Delineating the Role of Toll-Like Receptors in Inflammatory Bowel Disease.

Critical Roles of G Protein-Coupled Receptors in Regulating Intestinal Homeostasis and Inflammatory Bowel Disease

Toll-like receptors in inflammatory bowel disease: A review of the role of phytochemicals

Targeting of Costimulatory Molecules As a Therapeutic Approach in Inflammatory Bowel Disease

Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics

Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer

Roles of G Protein-Coupled Receptors in Inflammatory Bowel Disease.

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing

Systemic Toll-like Receptor Ligands Modify B-cell Responses in Human Inflammatory Bowel Disease.

New Insights into Bacterial Mechanisms and Potential Intestinal Epithelial Cell Therapeutic Targets of Inflammatory Bowel Disease

Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease

IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease

The Immunopathogenesis and Therapies of Inflammatory Bowel Diseases

After Interleukin-12P40, Are Interleukin-23 and Interleukin-17 the Next Therapeutic Targets for Inflammatory Bowel Disease?

Toll-like Receptor Activation by Helminths or Helminth Products to Alleviate Inflammatory Bowel Disease

Toll-like Receptors As Therapeutic Targets for Autoimmune Connective Tissue Diseases.

TRP channels in inflammatory bowel disease: Potential therapeutic targets

TLR5 Signaling in the Regulation of Intestinal Mucosal Immunity